Micah John Luderer1, Barbara Muz1, Pilar de la Puente1, Sanmathi Chavalmane2, Vaishali Kapoor1, Raymundo Marcelo1, Pratim Biswas2, Dinesh Thotala1, Buck Rogers1, Abdel Kareem Azab3. 1. Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, Missouri, 63108, USA. 2. Department of Energy, Environmental and Chemical Engineering, Washington University in St. Louis, St. Louis, Missouri, 63130, USA. 3. Department of Radiation Oncology, Cancer Biology Division, Washington University in St. Louis School of Medicine, 4511 Forest Park Ave., Room 3103, St. Louis, Missouri, 63108, USA. aazab@radonc.wustl.edu.
Abstract
PURPOSE: Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation has been limited by the poor tumor selectivity of agents. To address this unmet need, a boronated 2-nitroimidazole derivative (B-381) was synthesized and evaluated for its capability of targeting hypoxic glioma cells. METHODS: B-381 has been synthesized from a 1-step reaction. Using D54 and U87 glioma cell lines, the in vitro cytotoxicity and cellular accumulation of B-381 has been evaluated under normoxic and hypoxic conditions compared to L-boronophenylalanine (BPA). Furthermore, tumor retention of B-381 was evaluated in vivo. RESULTS: B-381 had low cytotoxicity in normal and cancer cells. Unlike BPA, B-381 illustrated preferential retention in hypoxic glioma cells compared to normoxic glioma cells and normal tissues in vitro. In vivo, B-381 illustrated significantly higher long-term tumor retention compared to BPA, with 9.5-fold and 6.5-fold higher boron levels at 24 and 48 h, respectively. CONCLUSIONS: B-381 represents a new class of BNCT agents in which their selectivity to tumors is based on hypoxic tumor metabolism. Further studies are warranted to evaluate B-381 and similar compounds as preclinical candidates for future BNCT clinical trials for the treatment of glioma.
PURPOSE:Boron neutron capture therapy (BNCT) has the potential to become a viable cancer treatment modality, but its clinical translation has been limited by the poor tumor selectivity of agents. To address this unmet need, a boronated 2-nitroimidazole derivative (B-381) was synthesized and evaluated for its capability of targeting hypoxic glioma cells. METHODS:B-381 has been synthesized from a 1-step reaction. Using D54 and U87glioma cell lines, the in vitro cytotoxicity and cellular accumulation of B-381 has been evaluated under normoxic and hypoxic conditions compared to L-boronophenylalanine (BPA). Furthermore, tumor retention of B-381 was evaluated in vivo. RESULTS:B-381 had low cytotoxicity in normal and cancer cells. Unlike BPA, B-381 illustrated preferential retention in hypoxic glioma cells compared to normoxic glioma cells and normal tissues in vitro. In vivo, B-381 illustrated significantly higher long-term tumor retention compared to BPA, with 9.5-fold and 6.5-fold higher boron levels at 24 and 48 h, respectively. CONCLUSIONS:B-381 represents a new class of BNCT agents in which their selectivity to tumors is based on hypoxic tumor metabolism. Further studies are warranted to evaluate B-381 and similar compounds as preclinical candidates for future BNCT clinical trials for the treatment of glioma.
Authors: Andrea Wittig; Laurence Collette; Klaas Appelman; Sandra Bührmann; Martin C Jäckel; Karl-Heinz Jöckel; Kurt Werner Schmid; Uta Ortmann; Raymond Moss; Wolfgang A G Sauerwein Journal: J Cell Mol Med Date: 2009-07-10 Impact factor: 5.310
Authors: Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff Journal: Lancet Oncol Date: 2009-03-09 Impact factor: 41.316
Authors: S J Liberman; A Dagrosa; R A Jiménez Rebagliati; M R Bonomi; B M Roth; L Turjanski; S I Castiglia; S J González; P R Menéndez; R Cabrini; M J Roberti; D A Batistoni Journal: Appl Radiat Isot Date: 2004-11 Impact factor: 1.513
Authors: Subhash Chandra; Rolf F Barth; Syed A Haider; Weilian Yang; Tianyao Huo; Aarif L Shaikh; George W Kabalka Journal: PLoS One Date: 2013-09-18 Impact factor: 3.240
Authors: Adam Noble; Riccardo S Mega; Daniel Pflästerer; Eddie L Myers; Varinder K Aggarwal Journal: Angew Chem Int Ed Engl Date: 2018-01-26 Impact factor: 15.336